Clinical benefit for moderate-to-severe plaque psoriasis patients treated with Raptiva for 30 months

Genentech and XOMA have announced preliminary 30-month (120 weeks) results from an open-label study evaluating the safety and efficacy of long-term continuous treatment with RAPTIVA® (efalizumab) in adults with moderate-to-severe chronic plaque psoriasis.

The study results were presented as a poster at the American Academy of Dermatology ACADEMY 2004 meeting in New York. The results of this study suggest that continuous, weekly dosing of RAPTIVA provided sustained clinical benefit over 2 1/2 years.

Of the 159 subjects participating in the study who completed 30 months of treatment, a 75 percent or greater improvement on the Psoriasis Area Severity Index (PASI 75) was observed in 78 percent (124/159) of patients with weekly RAPTIVA therapy. Ninety-one percent (145/159) of patients achieved a PASI 50 response, and 45 percent of patients (71/159) achieved a 90 percent or greater PASI improvement (PASI 90).

"Given that psoriasis is a chronic condition, dermatologists are looking for treatment options that can provide these patients with continuous control of their disease over the long-term," said Craig Leonardi, M.D., associate clinical professor of dermatology at St. Louis University Medical School, St. Louis, Mo., and a study investigator. "These data represent the first 30-month data available for any advanced therapy for plaque psoriasis and support the continued use of RAPTIVA as an important treatment option for patients afflicted with this chronic disease."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Keto diet may cause skin problems